T1	Participants 251 290	patients with high-risk prostate cancer
T2	Participants 354 366	168 patients
T3	Participants 622 634	All patients
T4	Participants 915 953	the patients developing acute toxicity
T5	Participants 977 1005	the two fractionation groups
T6	Participants 1860 1884	the two treatment groups
